Neurizon Therapeutics Teams Up with GenieUs Genomics to Leverage Cutting-Edge Genomic Profiling in NUZ-001 Phase 1 Trial
GenieUs Genomics (“GenieUs”) is excited to provide advanced genomic analysis for Neurizon Therapeutics Limited’s (“Neurizon”; ASX:NUZ; ASX:NUZOA) Phase 1 clinical trial of monepantel, now known as NUZ-001, marking an important step in understanding the genetic landscape of ALS patients.










